Determination of Probiotics Prescription Indications in Patients with Irritable Bowel Syndrome (Materials of the Expert Council and Literature Review)
V. T. Ivashkin,
I. V. Maev,
O. P. Alekseeva,
S. A. Alekseenko,
N. V. Korochanskaya,
E. A. Poluektova,
V. I. Simanenkov,
A. S. Trukhmanov,
I. B. Khlynov,
V. V. Tsukanov,
O. S. Shifrin,
T. L. Lapina,
R. V. Maslennikov,
A. I. Ulyanin https://doi.org/10.22416/1382-4376-2022-32-2-9-18
Abstract
Aim. To review the main indications for probiotics prescription in patients with irritable bowel syndrome and to present the materials of an Expert Council, which was held on 18 March 2022 in Moscow.
Key points. Gut microbiota disturbance is an integral part of irritable bowel syndrome (IBS) pathogenesis. Changes of colonic microbiota composition are associated with its functional potential modification, which leads to an increasing of the pro-inflammatory immune response, as well as to an exacerbation of the disease symptoms and quality of life decreasing in patients with IBS. The novel coronavirus infection (COVID-19) is an independent risk factor for both exacerbation and onset of IBS, which predispose to increase IBS incidence. Correction of gut microbiota composition with probiotics seems to be a promising therapeutic target for IBS treatment optimizing. The optimal probiotic should be effective, safe, strain-specific, and its dose and duration of administration should be confirmed by the results of clinical studies. Some of the probiotics with proven efficacy in IBS are Alflorex® and Enterol®.
Conclusion. Prescription of certain probiotics in IBS is advisable to normalize the frequency and consistency of stools, relieve abdominal pain and bloating, as well as improve patients’ quality of life.
Keywords
irritable bowel syndrome,
novel coronavirus infection,
COVID-19,
probiotics,
Bifidobacterium longum 35624,
Alflorex®,
Saccharomyces boulardii CNCM I-745,
Enterol®
Supporting agencies: The Expert Council was held under the technical support of the «Biocodex» pharmaceutical company
About the Authors
V. T. Ivashkin
Sechenov First Moscow State Medical University (Sechenov University)
Vladimir T. Ivashkin — Dr. Sci. (Med.), RAS Academician, Prof., Departmental Head, Department of Propaedeutics of Internal Diseases
119435, Moscow, Pogodinskaya str., 1, bld. 1
I. V. Maev
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Igor V. Maev — Dr. Sci. (Med.), Full Member of the Russian Academy of Sciences, Prof., Head of the Chair of Internal Disease Propaedeutics and Gastroenterology
127473, Moscow, Delegatskaya str., 20, bld. 1
O. P. Alekseeva
Privolzhsky Research Medical University
Olga P. Alekseeva — Dr. Sci. (Med.), Prof., Chair of Hospital Therapy and General Practice named after V.G. Vogralik
603005, Nizhny Novgorod, Minina i Pozharskogo sq., 10/1
S. A. Alekseenko
Far-Eastern State Medical University
Sergey A. Alekseenko — Dr. Sci. (Med.), Head of the Chairof Hospital Therapy;
Head of the Internal Medicine Clinic, Khabarovsk-1 Railway
Station Clinical Hospital, Far-Eastern Railways
680000, Khabarovsk, Zaparina str., 83
N. V. Korochanskaya
Kuban State Medical University
Natalia V. Korochanskaya — Dr. Sci. (Med.), Prof., Chair of Surgery No. 3; Head of the Centre for Gastroenterology, Territorial Clinical Hospital No. 2
350063; Krasnodar, Mitrofana Sedina str., 4
E. A. Poluektova
Sechenov First Moscow State Medical University (Sechenov
University)
Elena A. Poluektova — Dr. Sci. (Med.), Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine
119991, Moscow, Pogodinskaya str., 1, bld. 1
V. I. Simanenkov
I.I. Mechnikov North-West State Medical University
Vladimir I. Simanenkov — Dr. Sci. (Med.), Prof., Chair of Internal Diseases, Clinical Pharmacology and Nephrology
191015, St.-Petersburg, Kirochnaya str., 41
A. S. Trukhmanov
Sechenov First Moscow State Medical University (Sechenov University)
Alexander S. Trukhmanov — Dr. Sci. (Med.), Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology , Sklifosovsky Institute of Clinical Medicine
119991, Moscow, Pogodinskaya str., 1, bld. 1
I. B. Khlynov
Ural State Medical University
Igor B. Khlynov — Dr. Sci. (Med.), Assoc. Prof., Chair of Intermediate Therapy and Geriatrics
620028, Ekaterinburg, Repina str., 3
V. V. Tsukanov
Research Institute for Medical Problems in the North — Division of Krasnoyarsk Scientific Centre of the Siberian Branch of the RAS
Vladislav V. Tsukanov — Dr. Sci. (Med.), Prof., Head of the Clinical Department of Adult and Infant Digestive Pathology
660022, Krasnoyarsk, Partizana Zheleznyaka str., 3Г
O. S. Shifrin
Sechenov First Moscow State Medical University (Sechenov University)
Oleg S. Shifrin — Dr. Sci. (Med.), Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine; Head of the Department of Chronic Intestinal and Pancreatic Diseases, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology
119991, Moscow, Pogodinskaya str., 1, bld. 1
T. L. Lapina
Sechenov First Moscow State Medical University (Sechenov University)
Tatiana L. Lapina — Cand. Sci. (Med.), Assoc. Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine
119991, Moscow, Pogodinskaya str., 1, bld. 1
R. V. Maslennikov
Sechenov First Moscow State Medical University (Sechenov University)
Roman V. Maslennikov — Cand. Sci. (Med.), Research Assistant, Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine
119991, Moscow, Pogodinskaya str., 1, bld. 1
A. I. Ulyanin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Anatoly I. Ulyanin — Gastroenterologist, Department of Chronic Intestinal and Pancreatic Diseases, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology
119991, Moscow, Pogodinskaya str., 1, bld. 1
References
1. Puebla-Barragan S., Reid G. Forty-five-year evolution of probiotic therapy. Microb Cell. 2019;6(4):184–96. DOI: 10.15698/mic2019.04.673
2. World Gastroenterology Organisation. Probiotics and prebiotics. 2017. https://www.worldgastroenterology.org/guidelines
3. Markowiak P., Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9(9):1021. DOI: 10.3390/nu9091021
4. Grumet L., Tromp Y., Stiegelbauer V. The Development of High-Quality Multispecies Probiotic Formulations: From Bench to Market. Nutrients. 2020;12(8):2453. DOI: 10.3390/nu12082453
5. Forssten S.D., Laitila A., Maukonen J., Ouwehand A.C. Probiotic triangle of success; strain production, clinical studies and product development. FEMS Microbiol Lett. 2020;367(19):fnaa167. DOI: 10.1093/femsle/fnaa167
6. Ivashkin V.T., Maev I.V., Abdulganieva D.I., Alekseenko S.A., Gorelov A.V., Zakharova I.N., et al. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Rus J Gastroenterol Hepatol Coloproctol. 2021;31(2):65–91 (In Russ.). DOI: 10.22416/1382-4376-2021-31-2-65-91
7. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;(11):CD003048. DOI: 10.1002/14651858.CD003048.pub3
8. Höchter W., Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wochenschr. 1990;(132):188–92.
9. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., Johnsen B., Shekelle P.G. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–69. DOI: 10.1001/jama.2012.3507
10. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095. DOI: 10.1002/14651858.CD006095.pub4
11. Choi C.H., Jo S.Y., Park H.J., Chang S.K., Byeon J.S., Myung S.J. A randomized, double-blind, placebocontrolled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011;45(8):679–83. DOI: 10.1097/MCG.0b013e318204593e
12. Camilleri M. Irritable Bowel Syndrome: Straightening the road from the Rome criteria. Neurogastroenterol Motil. 2020;32(11):e13957. DOI: 10.1111/nmo.13957
13. Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A., et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Rus J Gastroenterol, Hepatol, Coloproctol. 2021;31(5):74–95 (In Russ.). DOI: 10.22416/1382-4376-2021-31-5-74-95
14. Oka P., Parr H., Barberio B., Black C.J., Savarino E.V., Ford A.C. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908–17. DOI: 10.1016/S2468-1253(20)30217-X
15. Sperber A.D., Bangdiwala S.I., Drossman D.A., Ghoshal U.C., Simren M., Tack J., et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. DOI: 10.1053/j. gastro.2020.04.014
16. Chandar A.K. Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide. Int J Gen Med. 2017;10:385–93. DOI: 10.2147/IJGM.S126581
17. Wall G.C., Bryant G.A., Bottenberg M.M., Maki E.D., Miesner A.R. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol. 2014;20(27):8796–806. DOI: 10.3748/wjg.v20.i27.8796
18. Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–61; quiz 1546, 1562. DOI: 10.1038/ajg.2014.202
19. Oshima T., Siah K.T.H., Yoshimoto T., Miura K., Tomita T., Fukui H., Miwa H. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2021;36(7):1820–7. DOI: 10.1111/jgh.15346
20. Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159(3):944–55.e8. DOI: 10.1053/j.gastro.2020.05.048
21. Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clin Infect Dis. 2020;71(10):2669–78. DOI: 10.1093/cid/ciaa709
22. Yeoh Y.K., Zuo T., Lui G.C., Zhang F., Liu Q., Li A.Y., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70(4):698–706. DOI: 10.1136/gutjnl-2020-323020
23. Tao W., Zhang G., Wang X., Guo M., Zeng W., Xu Z., et al. Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18. Med Microecol. 2020;5:100023. DOI: 10.1016/j.medmic.2020.100023
24. Moser G., Fournier C., Peter J. Intestinal microbiomegut-brain axis and irritable bowel syndrome. Wien Med Wochenschr. 2018;168(3–4):62–6. DOI: 10.1007/s10354-017-0592-0
25. Ghoshal U.C., Ghoshal U., Rahman M.M., Mathur A., Rai S., Akhter M., et al. Post-infection functional gastrointestinal disorders following coronavirus disease-19: A case-control study. J Gastroenterol Hepatol. 2022;37(3):489–98. DOI: 10.1111/jgh.15717
26. Groeger D., O’Mahony L., Murphy E.F., Bourke J.F., Dinan T.G., Kiely B., et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013;4(4):325–39. DOI: 10.4161/gmic.25487
27. Tariq R., Saha S., Furqan F., Pardi D., Khanna S. In reply-Lack of Marked Association Between Gastrointestinal Symptoms and COVID-19 Mortality: An Updated Meta-analysis Based on Adjusted Effect Estimates. Mayo Clin Proc. 2021;96(6):1680–1. DOI: 10.1016/j.mayocp.2021.04.010
28. Maslennikov R., Svistunov A., Ivashkin V., Ufimtseva A., Poluektova E., Efremova I., et al. Early viral versus late antibiotic-associated diarrhea in novel coronavirus infection. Medicine (Baltimore). 2021;100(41):e27528. DOI: 10.1097/MD.0000000000027528
29. Ivashkin V., Fomin V., Moiseev S., Brovko M., Maslennikov R., Ulyanin A., et al. Efficacy of a Probiotic Consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the Treatment of Hospitalized Patients with COVID-19: a Randomized Controlled Trial. Probiotics Antimicrob Proteins. 2021:1–9. DOI: 10.1007/s12602-021-09858-5
30. Voth E., Khanna S. The Integrative Human microbiome project: a mile stone in the understanding of the gut microbiome. Expert Rev Gastroenterol Hepatol. 2020;14(8):639– 42. DOI: 10.1080/17474124.2020.1780912
31. Su G.L., Ko C.W., Bercik P., Falck-Ytter Y., Sultan S., Weizman A.V., Morgan R.L. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):697–705. DOI: 10.1053/j.gastro.2020.05.059
32. Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjørsvik B.R., Haleem N., Benitez-Paez A., et al. Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome. World J Gastroenterol. 2022;28(4):412–31. DOI: 10.3748/wjg.v28.i4.412
33. Ahlawat S., Asha, Sharma K.K. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol. 2021;72(6):636–68. DOI: 10.1111/lam.13333
34. Hillestad E.M.R., van der Meeren A., Nagaraja B.H., Bjørsvik B.R., Haleem N., Benitez-Paez A., et al. Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome. World J Gastroenterol. 2022;28(4):412–31. DOI: 10.3748/wjg.v28.i4.412
35. Sun J.R., Kong C.F., Qu X.K., Deng C., Lou Y.N., Jia L.Q. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Saudi J Gastroenterol. 2020;26(2):66–77. DOI: 10.4103/sjg.SJG_384_19
36. Sabaté J.M., Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol. 2022;28(7):732–44. DOI: 10.3748/wjg.v28.i7.732
37. Marazziti D., Buccianelli B., Palermo S., Parra E., Arone A., Beatino M.F., et al. The Microbiota/Microbiome and the Gut-Brain Axis: How Much Do They Matter in Psychiatry? Life (Basel). 2021;11(8):760. DOI: 10.3390/life11080760
38. Chin V.K., Yong V.C., Chong P.P., Amin Nordin S., Basir R., Abdullah M. Mycobiome in the Gut: A Multiperspective Review. Mediators Inflamm. 2020;2020:9560684. DOI: 10.1155/2020/9560684
39. Czerucka D., Rampal P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World J Gastroenterol. 2019;25(18):2188–203. DOI: 10.3748/wjg.v25.i18.2188
40. Moré M.I., Vandenplas Y. Saccharomyces boulardii CNCM I-745 Improves Intestinal Enzyme Function: A Trophic Effects Review. Clin Med Insights Gastroenterol. 2018;11:1179552217752679. DOI: 10.1177/1179552217752679
41. Stier H., Bischoff S.C. Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system. Clin Exp Gastroenterol. 2016;9:269–79. DOI: 10.2147/CEG.S111003
42. Terciolo C., Dapoigny M., Andre F. Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption. Clin Exp Gastroenterol. 2019;12:67–82. DOI: 10.2147/CEG.S181590
43. Constante M., De Palma G., Lu J., Jury J., Rondeau L., Caminero A., et al. Saccharomyces boulardii CNCM I-745 modulates the microbiota-gut-brain axis in a humanized mouse model of Irritable Bowel Syndrome. Neurogastroenterol Motil. 2021;33(3):e13985. DOI: 10.1111/nmo.13985
44. McFarland L.V., Karakan T., Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. E Clinical Medicine. 2021;41:101154. DOI: 10.1016/j.eclinm.2021.101154
Review
For citations:
Ivashkin V.T., Maev I.V., Alekseeva O.P., Alekseenko S.A., Korochanskaya N.V., Poluektova E.A., Simanenkov V.I., Trukhmanov A.S., Khlynov I.B., Tsukanov V.V., Shifrin O.S., Lapina T.L., Maslennikov R.V., Ulyanin A.I. Determination of Probiotics Prescription Indications in Patients with Irritable Bowel Syndrome (Materials of the Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(2):9-18. https://doi.org/10.22416/1382-4376-2022-32-2-9-18
Views:
1671
Email this article 
